Filtered By:
Source: Thrombosis and Haemostasis
Condition: Bleeding

This page shows you your search results in order of date. This is page number 9.

Order by Relevance | Date

Total 164 results found since Jan 2013.

Effectiveness and safety of rivaroxaban therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry.
Abstract The effectiveness and safety of rivaroxaban for stroke prevention in atrial fibrillation (SPAF) demonstrated in ROCKET AF needs to be confirmed in daily care. To evaluate effectiveness and safety of rivaroxaban therapy in SPAF patients in daily care, we used data from an ongoing, prospective, non-interventional registry of more than 2700 patients on novel oral anticoagulants in daily care. Between October 1, 2011 and February 28, 2013, a total of 1204 SPAF patients receiving rivaroxaban were enrolled. During a mean follow-up of 796.2 ± 207.3 days, the combined endpoint of stroke/transient ischaemic attac...
Source: Thrombosis and Haemostasis - January 21, 2016 Category: Hematology Authors: Hecker J, Marten S, Keller L, Helmert S, Michalski F, Werth S, Sahin K, Tittl L, Beyer-Westendorf J Tags: Thromb Haemost Source Type: research

Prediction models for intracranial hemorrhage or major bleeding in patients on antiplatelet therapy: a systematic review and external validation study.
CONCLUSION: A limited number of prediction models is available that predict intracranial hemorrhage or major bleeding in patients on antiplatelet therapy. Methodological quality of the models varied, but was generally low. Predictive performance in patients with cerebral ischemia was poor. In order to reliably predict the risk of bleeding in patients with cerebral ischemia, development of a prediction model according to current methodological standards is needed. This article is protected by copyright. All rights reserved. PMID: 26563743 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - November 12, 2015 Category: Hematology Authors: Hilkens NA, Algra A, Greving JP Tags: J Thromb Haemost Source Type: research

Incorporating edoxaban into the choice of anticoagulants for atrial fibrillation.
Abstract The non-vitamin K antagonist oral anticoagulants (NOACs) are replacing warfarin for stroke prevention in many patients with nonvalvular atrial fibrillation. Edoxaban, an oral factor Xa inhibitor, is the newest entrant in this class. Results of the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation (ENGAGE AF) study demonstrate that edoxaban is noninferior to warfarin for prevention of stroke and systemic embolic events, and is associated with significantly less major bleeding, including intracranial bleeding, and reduced cardiovascular mortality. With a net clinical benefit ov...
Source: Thrombosis and Haemostasis - October 15, 2015 Category: Hematology Authors: Weitz JI, Eikelboom J Tags: Thromb Haemost Source Type: research

Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation.
In conclusion, in routine care of patients with non-valvular atrial fibrillation, dabigatran treatment resulted in improved health outcomes compared with warfarin. PMID: 26446507 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - October 8, 2015 Category: Hematology Authors: Seeger JD, Bykov K, Bartels DB, Huybrechts K, Zint K, Schneeweiss S Tags: Thromb Haemost Source Type: research

A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system.
In conclusion, compared with warfarin, dabigatran treatment was associated with a lower risk of stroke and most outcomes measured, but increased incidence of major lower GI bleeding. PMID: 26446456 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - October 8, 2015 Category: Hematology Authors: Villines TC, Schnee J, Fraeman K, Siu K, Reynolds MW, Collins J, Schwartzman E Tags: Thromb Haemost Source Type: research

Acute hemorrhagic complications are associated with lower coated-platelet levels in non-lacunar brain infarction.
CONCLUSIONS: Lower levels of procoagulant platelets are associated with acute hemorrhagic complications following non-lacunar ischemic stroke. These results suggest a role for coated-platelets in risk/benefit assessment in the early stages of stroke. This article is protected by copyright. All rights reserved. PMID: 26426364 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - October 1, 2015 Category: Hematology Authors: Prodan CI, Stoner JA, Dale GL Tags: J Thromb Haemost Source Type: research

Dabigatran use in elderly patients with atrial fibrillation.
Abstract In elderly patients (≥ 75 years), evidence of dabigatran efficacy is lacking and increased vigilance is warranted. We aimed to assess dabigatran effectiveness and safety in elderly patients in real-world practice. We conducted a population-based study using administrative databases, in Quebec (1999-2013). Dabigatran users (110/150 mg) were compared with matched warfarin users with regard to stroke and bleeding events. Age was categorised into < 75 or ≥ 75 years. Propensity score adjusted models were used. The cohort consisted of 15,918 dabigatran users and 47,192 matched warfarin users, with ...
Source: Thrombosis and Haemostasis - September 10, 2015 Category: Hematology Authors: Avgil-Tsadok M, Jackevicius CA, Essebag V, Eisenberg M, Rahme E, Behlouli H, Pilote L Tags: Thromb Haemost Source Type: research

Hemodialysis for the treatment of dabigatran-associated bleeding: a case report and systematic review.
CONCLUSIONS: In patients with dabigatran associated bleeding, RRT appears to be effective in reducing dabigatran concentrations and in case reports this has been associated with a reduction in duration and/or severity of bleeding. However, a rebound in concentrations may be seen following withdrawal of RRT suggesting that a prolonged course of RRT may be more effective. This article is protected by copyright. All rights reserved. PMID: 26270886 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - August 13, 2015 Category: Hematology Authors: Chai-Adisaksopha C, Hillis C, Lim W, Boonyawat K, Moffat K, Crowther M Tags: J Thromb Haemost Source Type: research

A Phase II, Double-Blind, Randomized, Parallel Group, Dose Finding Study of the Safety and Tolerability of Darexaban Compared with Warfarin in Patients with Non-Valvular Atrial Fibrillation.
CONCLUSIONS: In this Phase II study in patients with NVAF, a lower bleeding rate was observed in the 120mg daily dose group of darexaban compared to warfarin and plasma D-dimer as marker for haemostasis was reduced. Further investigation of the optimal dose of darexaban for the prevention of stroke in patients with NVAF would need to be considered. This article is protected by copyright. All rights reserved. PMID: 26052866 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - June 6, 2015 Category: Hematology Authors: Lip GY, Halperin JL, Petersen P, Rodgers GM, Pall D, Renfurm RW Tags: J Thromb Haemost Source Type: research

Impact of bridging with perioperative low-molecular-weight heparin on cardiac and bleeding outcomes of stented patients undergoing non-cardiac surgery.
In conclusion, LMWH bridging in patients with coronary stents undergoing surgery is a common and possibly harmful practice, resulting in worse ischaemic outcomes at 30 days, and a significant risk of bleeding. PMID: 26017898 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - May 28, 2015 Category: Hematology Authors: Capodanno D, Musumeci G, Lettieri C, Limbruno U, Senni M, Guagliumi G, Valsecchi O, Angiolillo DJ, Rossini R Tags: Thromb Haemost Source Type: research

Selection, management, and outcome of vitamin K antagonist-treated patients with atrial fibrillation not switched to novel oral anticoagulants. Results from the Dresden NOAC registry.
In conclusion, in daily care, AF patients selected for VKA therapy are healthier than those treated with NOAC, demonstrate a high quality of anticoagulant control and very low stroke rates. However, the risk of major VKA bleeding is unacceptably high despite adequate patient selection and INR control and bleeding outcome is poor. PMID: 25994496 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - May 21, 2015 Category: Hematology Authors: Michalski F, Tittl L, Werth S, Hänsel U, Pannach S, Sahin K, Weiss N, Beyer-Westendorf J Tags: Thromb Haemost Source Type: research

Factor XI and Contact Activation as Targets for Antithrombotic Therapy.
This article is protected by copyright. All rights reserved. PMID: 25976012 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - May 14, 2015 Category: Hematology Authors: Gailani D, Bane CE, Gruber A Tags: J Thromb Haemost Source Type: research

Predicting outcomes among patients with atrial fibrillation and heart failure receiving anticoagulation with warfarin.
In conclusion, we developed a HF severity model using easily available clinical characteristics that performed well to risk-stratify patients with HF who are receiving anticoagulation for AF with regard to major haemorrhage. PMID: 25948532 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - May 7, 2015 Category: Hematology Authors: Kim EJ, Ozonoff A, Hylek EM, Berlowitz DR, Ash AS, Miller DR, Zhao S, Reisman JI, Jasuja GK, Rose AJ Tags: Thromb Haemost Source Type: research

Post-operative arterial thrombosis with non-vitamin K antagonist oral anticoagulants after total hip or knee arthroplasty.
In conclusion, in RCTs of pharmacological VTE prophylaxis in patients undergoing THR or TKR, there was no difference in the incidence of post-operative AT among patients treated with NOACs, compared to those treated with enoxaparin. PMID: 25946985 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - May 7, 2015 Category: Hematology Authors: Squizzato A, Lussana F, Cattaneo M Tags: Thromb Haemost Source Type: research

Antithrombotic Therapy for Left Ventricular Assist Devices in Adults: a Systematic Review.
CONCLUSIONS: Of 977 manuscripts, 24 articles met the inclusion criteria of adults with implanted LVADs where clinical outcomes were defined based on anticoagulant and/or antiplatelet regimen. Most studies reported treatment with unfractionated heparin post-operatively which was transitioned to a vitamin K antagonist (VKA). Goal INR varied between 1.5-3.5. Antiplatelet regimens ranged from no treatment to dual therapy. Definition of major bleeding differed between trials and incidence varied between 0% and 58%. The available evidence could not demonstrate a clear benefit of aspirin compared with VKA therapy alone [stroke R...
Source: Thrombosis and Haemostasis - April 6, 2015 Category: Hematology Authors: Kreuziger LB, Kim B, Wieselthaler GM Tags: J Thromb Haemost Source Type: research